Showing results (1531-1540 of 6,957) with videos related to
Sort By:
Pageof 696
Journal of Clinical Pharmacology|September 22, 2016
Allometry Is a Reasonable Choice in Pediatric Drug DevelopmentTao Liu, Parima Ghafoori, Jogarao V S GobburuJournal of Clinical Pharmacology|February 18, 2010
Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final resultsGengqian Cai, Jake J Thiessen, Charlotte A Baidoo, et al.Journal of Clinical Pharmacology|February 18, 2010
Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patientsSilke Retlich, Vincent Duval, Ulrike Graefe-Mody, et al.Journal of Clinical Pharmacology|July 1, 1989
The renal function and blood pressure effects of dilevalol in the normotensive and hypertensive elderlyG G Clifton, M E Cook, M Poland, et al.Journal of Clinical Pharmacology|July 1, 1989
Clinical pharmacology of dilevalol (II). The pharmacokinetic, pharmacodynamic, and tolerance studies of dilevalol during repeated administration in healthy subjectsA Fujimura, K Ohashi, M Tsuru, et al.Journal of Clinical Pharmacology|July 1, 1989
Effect of quinolone antimicrobials on theophylline pharmacokineticsR A Prince, E Casabar, C G Adair, et al.Journal of Clinical Pharmacology|September 23, 2016
Reinventing HCV Treatment: Past and Future PerspectivesWendy Carter, Sarah Connelly, Kimberly StrubleJournal of Clinical Pharmacology|June 2, 2017
Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With RitonavirChristian Wagner, Ping Zhao, Vikram Arya, et al.Journal of Clinical Pharmacology|June 16, 2017
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function ImpairmentNicolas Guérard, Christian Zwingelstein, Jasper DingemanseJournal of Clinical Pharmacology|June 1, 2017
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response AnalysesToshiyuki Tamai, Seiichi Hayato, Seiichiro Hojo, et al.Pageof 696